Trent M Woodruff Selected Research

phenylalanyl(ornithinyl- prolyl- cyclohexylalanyl- tryptophyl- arginyl)

4/2002

Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Trent M Woodruff Research Topics

Disease

34	Inflammation (Inflammations) 11/2023 - 01/2006
16	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2024 - 12/2008
11	Infections 01/2024 - 06/2010
11	Neuroinflammatory Diseases 01/2021 - 07/2009
11	Reperfusion Injury 01/2020 - 04/2002
9	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023 - 04/2010
9	Disease Progression 11/2020 - 05/2015
8	Neoplasms (Cancer) 05/2024 - 10/2019
7	Ischemia 01/2020 - 04/2002
7	Wounds and Injuries (Trauma) 01/2019 - 04/2002
6	Edema (Dropsy) 01/2015 - 04/2002
6	Stroke (Strokes) 06/2012 - 01/2008
5	Sepsis (Septicemia) 01/2024 - 08/2006
5	Body Weight (Weight, Body) 10/2020 - 05/2005
5	Spinal Cord Injuries (Spinal Cord Injury) 01/2019 - 06/2012
5	Neuralgia (Stump Neuralgia) 01/2018 - 10/2013
4	Thromboinflammation 04/2024 - 01/2019
4	COVID-19 11/2023 - 01/2020
4	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2023 - 06/2012
4	Ischemic Stroke 01/2020 - 01/2008
4	Alzheimer Disease (Alzheimer's Disease) 10/2019 - 04/2010
4	Necrosis 02/2019 - 05/2005
3	Bites and Stings (Sting) 01/2024 - 01/2020
3	Parkinson Disease (Parkinson's Disease) 01/2023 - 01/2016
3	Atherosclerosis 12/2021 - 07/2011
3	Pain (Aches) 01/2021 - 01/2016
3	Fibrosis (Cirrhosis) 01/2020 - 11/2011
3	Neural Tube Defects (Exencephaly) 03/2016 - 04/2013
3	Pre-Eclampsia (Preeclampsia) 09/2015 - 01/2013
3	Rheumatoid Arthritis 05/2012 - 03/2011
3	Neutropenia 08/2006 - 04/2002
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2005 - 11/2003
3	Colitis 08/2005 - 11/2003
2	Motor Neuron Disease (Primary Lateral Sclerosis) 01/2024 - 01/2008
2	Lung Injury 01/2024 - 08/2006
2	Diabetic Nephropathies (Diabetic Nephropathy) 11/2022 - 01/2020
2	Cancer Pain 10/2022 - 05/2020
2	Epilepsy (Aura) 01/2022 - 04/2015
2	Schizophrenia (Dementia Praecox) 01/2022 - 10/2019
2	Chronic Disease (Chronic Diseases) 01/2022 - 10/2019
2	Acute Lung Injury 01/2021 - 11/2012
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 08/2006
2	Hypertension (High Blood Pressure) 01/2020 - 11/2011
2	Meningococcal Infections 12/2019 - 01/2018
2	Carcinogenesis 10/2019 - 01/2016
2	Melanoma (Melanoma, Malignant) 10/2019 - 01/2016
2	Brain Injuries (Brain Injury) 10/2019 - 01/2008
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2018 - 06/2015
2	Burns 01/2018 - 08/2006
2	Hyperalgesia 01/2016 - 06/2015
2	Huntington Disease (Huntington's Disease) 01/2016 - 07/2006
2	Premature Birth (Birth, Premature) 08/2015 - 01/2013
2	Arthritis (Polyarthritis) 03/2011 - 09/2002

Drug/Important Bio-Agent (IBA)

57	Complement System Proteins (Complement)IBA 04/2024 - 04/2002
15	Anaphylatoxin C5a ReceptorIBA 10/2019 - 04/2002
12	Complement C5a (Complement 5a)IBA 11/2022 - 07/2011
9	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2004
7	Peptides (Polypeptides)IBA 01/2022 - 05/2012
6	LigandsIBA 01/2024 - 01/2015
6	Complement Receptors (Complement Receptor)IBA 12/2023 - 04/2015
6	InflammasomesIBA 07/2023 - 10/2017
5	Complement Inactivating AgentsIBA 01/2023 - 01/2008
5	Analgesics (Analgesic Drugs)IBA 10/2022 - 10/2013
5	Peroxidase (Myeloperoxidase)IBA 01/2022 - 11/2003
5	CytokinesIBA 01/2022 - 01/2015
5	hydrocinnamate- cyclo(ornithyl- prolyl- cyclohexylalanyl- tryptophyl- arginyl)IBA 01/2017 - 08/2005
5	AcPhe(ornithine- Pro- cyclohexylamine- Trp- Arg)IBA 01/2006 - 04/2002
4	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 09/2012
4	HMGB1 Protein (HMG1)IBA 01/2022 - 03/2013
4	AnaphylatoxinsIBA 12/2019 - 01/2016
4	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2019 - 08/2011
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2006 - 04/2002
3	EphrinsIBA 01/2024 - 11/2012
3	lepirudin (Refludan)FDA Link 01/2023 - 12/2021
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2020
3	Messenger RNA (mRNA)IBA 01/2021 - 10/2017
3	ChemokinesIBA 01/2021 - 10/2017
3	Protein AggregatesIBA 01/2020 - 12/2017
3	Folic Acid (Vitamin M)FDA LinkGeneric 03/2016 - 04/2013
3	Factor VaIBA 08/2015 - 04/2002
3	Cyclic PeptidesIBA 01/2006 - 04/2002
3	Sulfonic AcidsIBA 08/2005 - 11/2003
2	Antiviral Agents (Antivirals)IBA 04/2024 - 01/2020
2	dectin 1IBA 01/2024 - 01/2020
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2024 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2022
2	Ephrin-A1 (Ephrin A1)IBA 01/2024 - 11/2012
2	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 07/2023 - 10/2017
2	Therapeutic UsesIBA 01/2023 - 01/2011
2	VenomsIBA 11/2022 - 01/2021
2	Ketamine FDA LinkGeneric 10/2022 - 05/2020
2	CholesterolIBA 12/2021 - 01/2019
2	Receptor for Advanced Glycation End ProductsIBA 10/2020 - 01/2015
2	Interleukin-6 (Interleukin 6)IBA 10/2017 - 04/2015
2	CollagenIBA 01/2016 - 11/2011
2	Toll-Like Receptors (Toll-Like Receptor)IBA 05/2015 - 07/2009
2	Complement C3a (Complement 3a)IBA 12/2014 - 05/2012
2	AntigensIBA 03/2011 - 09/2002

Therapy/Procedure

15	Therapeutics 11/2023 - 07/2009
3	Drug Therapy (Chemotherapy) 01/2011 - 05/2004